Zobrazeno 1 - 10
of 4 262
pro vyhledávání: '"U. Jansen"'
Autor:
Chaitanya Kurhade, Jing Zou, Hongjie Xia, Mingru Liu, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Ping Ren, Xuping Xie, Kena A. Swanson, Pei-Yong Shi
Publikováno v:
Emerging Microbes and Infections, Vol 11, Iss 1, Pp 1828-1832 (2022)
Distinct SARS-CoV-2 Omicron sublineages have evolved showing increased fitness and immune evasion than the original Omicron variant BA.1. Here, we report the neutralization activity of sera from BNT162b2 vaccinated individuals or unimmunized Omicron
Externí odkaz:
https://doaj.org/article/daff56ad156a43d398c1caae173a8eba
Autor:
Michael W. Simon, Regine Bataille, Nicole S. Caldwell, Bradford D. Gessner, Luis Jodar, Erik Lamberth, Yahong Peng, Daniel A. Scott, Lanyu Lei, Peter C. Giardina, William C. Gruber, Kathrin U. Jansen, Allison Thompson, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
ABSTRACTUse of pneumococcal conjugate vaccines (PCVs) has led to substantial reductions in the global burden of pediatric pneumococcal disease. Expansion of serotype coverage has been achieved by increasing PCV valency, but this may carry the potenti
Externí odkaz:
https://doaj.org/article/eee4a903246c45198a86e37958cb0a5c
Autor:
Chaitanya Kurhade, Jing Zou, Hongjie Xia, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Xuping Xie, Kena A. Swanson, Pei‑Yong Shi
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-4 (2022)
It is essential to test the neutralization of approved vaccines against SARSCoV-2 Omicron sublineages. Kurhade et al. find that sera from people with three doses of BNT162b2 neutralize Omicron BA.1, BA.2, and BA.3 to a lesser extent than the original
Externí odkaz:
https://doaj.org/article/d14e142b43154ca1aba34a62462d7ea2
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
Autor:
Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Ugur Sahin, Xuping Xie, Philip R. Dormitzer, Pei-Yong Shi
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-4 (2022)
Abstract BNT162b2-elicited human sera neutralize the currently dominant Delta SARS-CoV-2 variant. Here, we report the ability of 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, to neutralize USA-WA1/2020 SARS-CoV-2 bearing variant spik
Externí odkaz:
https://doaj.org/article/d1191565f6484c56a7a3a8d7ac73402e
Autor:
Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J. Belanger, Bradford D. Gessner, Luis Jodar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
The aim of this post hoc analysis was to describe the immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adults with chronic medical conditions or smoking that place them at increased risk of developing pneumococcal disease. Da
Externí odkaz:
https://doaj.org/article/c1b7ed93b86145a38cb32c74e643741f
Autor:
Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 8, Pp 2691-2699 (2021)
Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional co
Externí odkaz:
https://doaj.org/article/e0a61e1e225742c5b2e9ce10b62e0c70
Autor:
David Fitz-Patrick, Mariano Young Jr, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William Gruber, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2249-2256 (2021)
Expanding serotype coverage of pneumococcal conjugate vaccines (PCVs) to target prevailing disease-causing serotypes could further reduce disease burden. To address this need, 2 different PCVs have been investigated: a 20-valent PCV (PCV20; includes
Externí odkaz:
https://doaj.org/article/0b3347e2452941a9b4e2d5703b0f8e80
Autor:
Judith Absalon, Raphael Simon, David Radley, Peter C. Giardina, Kenneth Koury, Kathrin U. Jansen, Annaliesa S. Anderson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 1 (2022)
Group B streptococcus (Streptococcus agalactiae, GBS) is an important cause of life-threatening disease in newborns. Pregnant women colonized with GBS can transmit the bacteria to the developing fetus, as well as to their neonates during or after del
Externí odkaz:
https://doaj.org/article/bb9a669cee1a4d8495518ab96bc7da63
Autor:
Allison R. Thompson, Nicola P. Klein, H. Jackson Downey, Scott Patterson, Vani Sundaraiyer, Wendy Watson, Keri Clarke, Kathrin U. Jansen, Shite Sebastian, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 2, Pp 444-451 (2019)
Immune responses to 13-valent pneumococcal conjugate vaccine (PCV13) and quadrivalent inactivated influenza vaccine (QIV) in older adults may vary with coadministration and previous pneumococcal polysaccharide vaccination. This study assessed safety
Externí odkaz:
https://doaj.org/article/538518ef02b44b0b88cb3f4861a8e7c6
Autor:
Beate Kampmann, Shabir A. Madhi, Iona Munjal, Eric A.F. Simões, Barbara A. Pahud, Conrado Llapur, Jeffrey Baker, Gonzalo Pérez Marc, David Radley, Emma Shittu, Julia Glanternik, Hasra Snaggs, James Baber, Philip Zachariah, Shaun L. Barnabas, Merlin Fausett, Tyler Adam, Nicole Perreras, Marlies A. Van Houten, Anu Kantele, Li-Min Huang, Louis J. Bont, Takeo Otsuki, Sergio L. Vargas, Joanna Gullam, Bruce Tapiero, Renato T. Stein, Fernando P. Polack, Heather J. Zar, Nina B. Staerke, María Duron Padilla, Peter C. Richmond, Kenneth Koury, Katherine Schneider, Elena V. Kalinina, David Cooper, Kathrin U. Jansen, Annaliesa S. Anderson, Kena A. Swanson, William C. Gruber, Alejandra Gurtman
Publikováno v:
New England Journal of Medicine. 388:1451-1464